Optimal Timing and Outcomes of Minimally Invasive Approach in Acute Biliary Pancreatitis

Mihai Faur; Sorin Radu Fleaca; Claudia Diana Gherman; Ciprian Ionut Bacila; Denisa Tanasescu; Dragos Serban; Laura Carina Tribus; Corneliu Tudor; Gabriel Catalin Smarandache; Daniel Ovidiu Costea; Mihail Silviu Tudosie; Dan Sabau; Gabriel Andrei Gangura; Ciprian Tanasescu

doi:10.12659/MSM.937016

07 July 2022 : Clinical Research

Optimal Timing and Outcomes of Minimally Invasive Approach in Acute Biliary Pancreatitis

Mihai Faur^12ABCE, Sorin Radu Fleaca

^1CDFG, Claudia Diana Gherman^3ACF, Ciprian Ionut Bacila^1CDFG, Denisa Tanasescu^4BCEF, Dragos Serban

^56CDF*, Laura Carina Tribus^78CDF, Corneliu Tudor

^6DEF, Gabriel Catalin Smarandache^96CDF, Daniel Ovidiu Costea^1011CEF, Mihail Silviu Tudosie^1213CEF, Dan Sabau^12ABCF, Gabriel Andrei Gangura^914DEF, Ciprian Tanasescu^12ABCF

DOI: 10.12659/MSM.937016

Med Sci Monit 2022; 28:e937016

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 1 General data of patients included in the study.

Parameter	Mild ABP (n=53)	Medium-severe ABP (n=24)	Severe ABP (n=57)	Total (n=143)	P value

Age (mean±SD, years)	60.2±13.2	61.7±8.2	64.6±10.4	62.3±11.4	0.175^*

Sex (female; male)	13 (24.5%)	11 (45.8%)	30 (52.6%)	54 (40.3%)	0.008^**
Sex (female; male)	40 (75.5%)	13 (54.2%)	27 (47.4%)	80 (59.7%)

% Urban	31 (58.5%)	3 (12.5%)	10 (17.5%)	44 (32.8%)	<0.001^**
% Rural	22 (41.5%)	21 (87.5%)	47 (82.5%)	90 (67.2%)

No. comorbidities	0.9±0.8	1.6±1	2.4±1.3	1.69±1.3	<0.001^*

Comorbidities (no. patients, %)
• Diabetes	0	5 (20.8%)	25 (43.9%)	30 (22.4%)	<0.001^**
• Obesity	0	0	20 (35.1%)	20 (14.9%)	<0.001^**
• Chronic broncho pneumopathy	0	2 (8.3%)	25 (43.9%)	27 (20.1%)	<0.001^**
• Arterial hypertension	27 (50.9%)	19 (62.5%)	23 (40.4%)	65 (48.5%)	0.191^**
• Ischemic coronary disease	19 (35.8%)	9 (37.5%)	35 (61.4%)	63 (47%)	0.02^**

Time from onset to hospitalization (days)	1.8±1.1	2.6±0.4	5.6±1.1	3.5±2	<0.001^*

Amylase (mean±SD, UI/L)	232.40±43.9	404.8±52.3	2067.8±777.9	1044±1020	<0.001^*

Bilirubin (mean±SD, mg/dL)	2±0.7	3.4±0.5	15.1±5	7.8±7.1	<0.001^*

ALT (mean±SD, UI/L)	75.4±18.4	275.5±41.6	681±110.8	368.9±288.5	<0.001^*

AST (mean±SD, UI/L)	88.7±21.2	323±50.2	646.4±138.6	367.9±270.8	<0.001^*

Leukocytes (mean±SD, nr/mmc)	12706±941.3	15422.5±779	22370.7±3947.7	17312.7±5200.4	<0.001^*

Leukocytes >15 000/mmc	0	18 (75%)	57 (100%)	75 (52.4%)	<0.001^**

NLR (mean±SD)	8.6±2.4	11.6±1.9	19.8±2.8	13.9±5.7	<0.001^*

Creatinine (mean±SD)	0.7±0.5	3.3±1	7.6±1.6	4.1±3.3	<0.001^*

Creatinine >2 (no. of patients,%)	0	20 (83.3%)	56 (98.2%)	76 (53.1%)	<0.001^**

Balthasar CT score at admission:
A	18 (34%)	0	0	18 (13.4%)	<0.001^**
B	33 (62%)	2 (8%)	0	35 (26.1%)
C	2 (4%)	21 (88%)	1 (2%)	24 (17.9%)
D	0	1 (4%)	50 (87.5%)	51 (38.1%)
E	0	0	6 (10.5%)	6 (4.5%)
^* Kruskal-Wallis Test; ^** Fisher exact test. ABP – acute biliary pancreatitis; ALT – alanine aminotransferase; AST – aspartate aminotransferase; CT – computed tomography; NLR – neutrophil-to-lymphocyte ratio; SD – standard deviation.

Back to the Article

Optimal Timing and Outcomes of Minimally Invasive Approach in Acute Biliary Pancreatitis

Your Privacy